MedinCell S.A. (EPA:MEDCL)
France · Delayed Price · Currency is EUR 29.82
0.00 (0.00%)
Nov 12, 2026, 9:23 AM CET
MedinCell Revenue
In the fiscal year ending March 31, 2026, MedinCell had annual revenue of 19.52M EUR, down -23.21%. MedinCell had revenue of 7.91M in the half year ending March 31, 2026, with 286.42% growth. That makes MedinCell the 32,069th largest company in the world by revenue and 404th in France.
Revenue
19.52M
Revenue Growth
-23.21%
P/S Ratio
44.11
Revenue / Employee
172.18K
Employees
141
Market Cap
1.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 19.52M | -5.90M | -23.21% |
| Mar 31, 2025 | 25.42M | 16.39M | 181.43% |
| Mar 31, 2024 | 9.03M | -857.00K | -8.67% |
| Mar 31, 2023 | 9.89M | 1.55M | 18.60% |
| Mar 31, 2022 | 8.34M | 152.00K | 1.86% |
| Mar 31, 2021 | 8.19M | 5.33M | 187.03% |
| Mar 31, 2020 | 2.85M | 1.41M | 97.78% |
| Mar 31, 2019 | 1.44M | -5.00M | -77.61% |
| Mar 31, 2018 | 6.44M | -2.09M | -24.54% |
| Mar 31, 2017 | 8.53M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 59.49M |
| Cellectis | 55.86M |
| Nanobiotix | 11.51M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
| Valerio Therapeutics Société anonyme | 5.55M |
MedinCell News
- 4 weeks ago - MedinCell downgraded to Hold from Buy at Kepler Cheuvreux - TheFly
- 4 weeks ago - Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026) - Business Wire
- 4 weeks ago - Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan - Business Wire
- 4 weeks ago - MedinCell Transcript: Investor update - Transcripts
- 4 weeks ago - MedinCell Press release: Investor update - Filings
- 4 weeks ago - Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine) - Business Wire
- 7 weeks ago - MedinCell initiated with an Outperform at Oppenheimer - TheFly
- 7 weeks ago - Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026 - Business Wire